Published in Curr Opin Lipidol on June 01, 2015
Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet (2013) 3.87
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature (2014) 3.29
A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis (2003) 2.97
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ (2008) 2.62
Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J (2008) 2.50
Familial hypercholesterolaemia: summary of NICE guidance. BMJ (2008) 2.18
Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet (2006) 1.76
Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab (2012) 1.70
Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment. Ann Hum Genet (2012) 1.53
Use of targeted exome sequencing as a diagnostic tool for Familial Hypercholesterolaemia. J Med Genet (2012) 1.29
Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin Chem Lab Med (2008) 1.25
Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart (2011) 1.15
Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations. J Med Genet (2014) 1.00
The use of next-generation sequencing in clinical diagnosis of familial hypercholesterolemia. Genet Med (2013) 1.00
Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26,406 individuals tested for genetic FH. Circ Cardiovasc Genet (2012) 0.96
Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. J Clin Lipidol (2014) 0.90
Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers. Atherosclerosis (2014) 0.90
Novel functional APOB mutations outside LDL-binding region causing familial hypercholesterolaemia. Hum Mol Genet (2013) 0.89
Genetic diagnosis of familial hypercholesterolaemia by targeted next-generation sequencing. J Intern Med (2014) 0.87
Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia. Curr Opin Lipidol (2010) 0.85
Identification and biochemical analysis of a novel APOB mutation that causes autosomal dominant hypercholesterolemia. Mol Genet Genomic Med (2013) 0.85
A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. Int J Cardiol (2013) 0.83
Targeted genetic testing for familial hypercholesterolaemia using next generation sequencing: a population-based study. BMC Med Genet (2014) 0.82
Diagnostic validation of a familial hypercholesterolaemia cohort provides a model for using targeted next generation DNA sequencing in the clinical setting. Pathology (2014) 0.81
Guidelines for the identification and management of patients with familial hypercholesterolaemia (FH): are we coming to a consensus? Atheroscler Suppl (2011) 0.81
Whole-exome sequencing in an extended family with myocardial infarction unmasks familial hypercholesterolemia. BMC Cardiovasc Disord (2014) 0.80
The reduced cost of providing a nationally recognised service for familial hypercholesterolaemia. Open Heart (2014) 0.79
Genetic mutations in patients with possible familial hypercholesterolaemia in South East Scotland. Scott Med J (2012) 0.77
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet (2012) 11.09
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet (2014) 4.13
The UK10K project identifies rare variants in health and disease. Nature (2015) 3.89
Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet (2013) 3.87
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Ecology. Managing soil carbon. Science (2004) 3.28
Gene co-expression network topology provides a framework for molecular characterization of cellular state. Bioinformatics (2004) 3.09
A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis (2003) 2.97
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol (2002) 2.84
Sex-stratified genome-wide association studies including 270,000 individuals show sexual dimorphism in genetic loci for anthropometric traits. PLoS Genet (2013) 2.83
Chromosome 9p21.3 coronary heart disease locus genotype and prospective risk of CHD in healthy middle-aged men. Clin Chem (2008) 2.82
Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. Nat Genet (2011) 2.73
Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol (2006) 2.70
Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ (2002) 2.55
Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study. BMJ (2010) 2.53
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study. Eur Heart J (2008) 2.52
Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am J Respir Crit Care Med (2002) 2.51
Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J (2008) 2.50
Endothelial nitric oxide synthase genotype and ischemic heart disease: meta-analysis of 26 studies involving 23028 subjects. Circulation (2004) 2.31
Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet (2002) 2.27
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol (2013) 2.18
Familial hypercholesterolaemia: summary of NICE guidance. BMJ (2008) 2.18
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet (2010) 2.15
Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol (2008) 2.14
Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. Am J Hum Genet (2009) 2.04
Left ventricular wall thickness and the presence of asymmetric hypertrophy in healthy young army recruits: data from the LARGE heart study. Circ Cardiovasc Imaging (2013) 1.98
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
Association of telomere length with type 2 diabetes, oxidative stress and UCP2 gene variation. Atherosclerosis (2009) 1.96
Inflammation, insulin resistance, and diabetes--Mendelian randomization using CRP haplotypes points upstream. PLoS Med (2008) 1.95
Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev (2008) 1.85
Three novel mutations in the apolipoprotein E gene in a sample of individuals with type 2 diabetes mellitus. Clin Chem (2004) 1.83
Peroxisome proliferator--activated receptor alpha gene regulates left ventricular growth in response to exercise and hypertension. Circulation (2002) 1.79
Comparative analysis of genome-wide association studies signals for lipids, diabetes, and coronary heart disease: Cardiovascular Biomarker Genetics Collaboration. Eur Heart J (2011) 1.73
Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial. Am J Med Genet A (2004) 1.72
In the elderly, interleukin-6 plasma levels and the -174G>C polymorphism are associated with the development of cardiovascular disease. Arterioscler Thromb Vasc Biol (2002) 1.70
Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol (2004) 1.70
Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. Am J Epidemiol (2006) 1.66
Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. Arterioscler Thromb Vasc Biol (2003) 1.65
Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol (2004) 1.61
Abdominal aortic aneurysm is associated with a variant in low-density lipoprotein receptor-related protein 1. Am J Hum Genet (2011) 1.60
Identification and management of familial hypercholesterolaemia: what does it mean to primary care? Br J Gen Pract (2009) 1.55
Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment. Ann Hum Genet (2012) 1.53
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
Telomeres are shorter in myocardial infarction patients compared to healthy subjects: correlation with environmental risk factors. J Mol Med (Berl) (2010) 1.51
Human apolipoprotein E isoforms differentially affect bone mass and turnover in vivo. J Bone Miner Res (2013) 1.47
Cascade testing in familial hypercholesterolaemia: how should family members be contacted? Eur J Hum Genet (2005) 1.46
Blood pressure loci identified with a gene-centric array. Am J Hum Genet (2011) 1.44
Bayesian meta-analysis of genetic association studies with different sets of markers. Am J Hum Genet (2008) 1.44
Influence of factor VII gene polymorphisms and environmental factors on plasma coagulation factor VII concentrations in middle-aged women with and without manifest coronary heart disease. Thromb Haemost (2005) 1.41
Psychological and behavioural impact of genetic testing smokers for lung cancer risk: a phase II exploratory trial. J Health Psychol (2008) 1.41
Variation in the lipoprotein lipase gene influences exercise-induced left ventricular growth. J Mol Med (Berl) (2006) 1.40
European differences in the association between ACE I/D polymorphism and incidence of MI may be explained by gene-lipid interaction. Atherosclerosis (2006) 1.39
ANGPTL4 E40K and T266M: effects on plasma triglyceride and HDL levels, postprandial responses, and CHD risk. Arterioscler Thromb Vasc Biol (2008) 1.34
APOE/C1/C4/C2 gene cluster genotypes, haplotypes and lipid levels in prospective coronary heart disease risk among UK healthy men. Mol Med (2010) 1.33
Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling. Circulation (2003) 1.31
Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol (2002) 1.31
Influence of common genetic variation on blood lipid levels, cardiovascular risk, and coronary events in two British prospective cohort studies. Eur Heart J (2012) 1.30
Public interest in genetic testing for susceptibility to heart disease and cancer: a population-based survey in the UK. Prev Med (2004) 1.30
Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study. J Lipid Res (2006) 1.28
Genetic variation in complement factor H and risk of coronary heart disease: eight new studies and a meta-analysis of around 48,000 individuals. Atherosclerosis (2010) 1.27
Lab-on-a-chip methods for point-of-care measurements of salivary biomarkers of periodontitis. Ann N Y Acad Sci (2007) 1.26
Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin Chem Lab Med (2008) 1.25
Telomere length in atherosclerosis and diabetes. Atherosclerosis (2009) 1.24
Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk. PLoS One (2012) 1.21
Awareness of lifestyle risk factors for cancer and heart disease among adults in the UK. Patient Educ Couns (2008) 1.20
Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Circulation (2009) 1.20
The functional interaction on in vitro gene expression of APOA5 SNPs, defining haplotype APOA52, and their paradoxical association with plasma triglyceride but not plasma apoAV levels. Biochim Biophys Acta (2008) 1.19
Meta-analysis of the INSIG2 association with obesity including 74,345 individuals: does heterogeneity of estimates relate to study design? PLoS Genet (2009) 1.18
Determination of the functionality of common APOA5 polymorphisms. J Biol Chem (2005) 1.18
Serum 25-hydroxyvitamin D concentration in subclinical carotid atherosclerosis. Arterioscler Thromb Vasc Biol (2013) 1.18
IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants' data from 21 studies. Diabetes (2006) 1.18
Cross-sectional analysis of baseline data to identify the major determinants of carotid intima-media thickness in a European population: the IMPROVE study. Eur Heart J (2009) 1.17
Integrated associations of genotypes with multiple blood biomarkers linked to coronary heart disease risk. Hum Mol Genet (2009) 1.17
The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men. Clin Sci (Lond) (2007) 1.17
APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study. J Lipid Res (2004) 1.16
Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol (2012) 1.14
PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. Circulation (2010) 1.14
Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory? Eur J Cardiovasc Prev Rehabil (2004) 1.14
Policy challenges of clinical genome sequencing. BMJ (2013) 1.14
Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS). Arterioscler Thromb Vasc Biol (2002) 1.12
Cardiovascular risk in healthy men and markers of oxidative stress in diabetic men are associated with common variation in the gene for uncoupling protein 2. Eur Heart J (2004) 1.12
Interleukin-6 receptor pathways in abdominal aortic aneurysm. Eur Heart J (2012) 1.12
Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges. Biochim Biophys Acta (2003) 1.12
Association of serum interleukin-6 concentration with a functional IL6 -6331T>C polymorphism. Clin Chem (2008) 1.11
Variation in USF1 shows haplotype effects, gene : gene and gene : environment associations with glucose and lipid parameters in the European Atherosclerosis Research Study II. Hum Mol Genet (2004) 1.11
Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation (2002) 1.11
Vitamin D receptor genotypes influence quadriceps strength in chronic obstructive pulmonary disease. Am J Clin Nutr (2008) 1.10
Peroxisome proliferator-activated receptor alpha gene variation influences age of onset and progression of type 2 diabetes. Diabetes (2005) 1.09
Does high C-reactive protein concentration increase atherosclerosis? The Whitehall II Study. PLoS One (2008) 1.09
Sequence variant on 9p21 is associated with the presence of abdominal aortic aneurysm disease but does not have an impact on aneurysmal expansion. Eur J Hum Genet (2008) 1.09